The Delhi High Court has directed Dr. Reddy's Labs to respond to Novo Nordisk's injunction petition concerning its weight-loss drug, semaglutide (Wegovy). Novo Nordisk alleges patent infringement, prompting the court's action. An IP expert suggests Dr. Reddy's Labs may need to justify its semaglutide exports, as Novo Nordisk's patent is set to expire in March of next year.